Literature DB >> 27131050

ACR Appropriateness criteria® for nasopharyngeal carcinoma.

Nabil F Saba1, Joseph K Salama2, Jonathan J Beitler3, Paul M Busse4, Jay S Cooper5, Christopher U Jones6, Shlomo Koyfman7, Harry Quon8, John A Ridge9, Farzan Siddiqui10, Francis Worden11, Min Yao12, Sue S Yom13.   

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) presents mostly with locally advanced disease and is treated with multimodal therapy; however, consensus is lacking for different clinical scenarios.
METHODS: The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
RESULTS: The ACR Expert Panel on Radiation Oncology - Head and Neck Cancer developed consensus recommendations for guiding management of nasopharyngeal carcinoma.
CONCLUSION: Multidisciplinary evaluation is essential to guiding the optimal use of surgery, radiation, and systemic therapy in this disease.
© 2015 Wiley Periodicals, Inc. Head Neck 38: 979-986, 2016. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Appropriateness criteria for nasopharyngeal cancer; cancer of the nasopharynx; nasopharyngeal carcinoma (NPC); squamous cell carcinoma of the nasopharynx

Mesh:

Year:  2016        PMID: 27131050     DOI: 10.1002/hed.24423

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  Neoantigen landscape in metastatic nasopharyngeal carcinoma.

Authors:  Mei Lin; Xiao-Long Zhang; Rui You; Qi Yang; Xiong Zou; Kai Yu; You-Ping Liu; Ru-Hai Zou; Yi-Jun Hua; Pei-Yu Huang; Jin Wang; Qi Zhao; Xiao-Bing Jiang; Jun Tang; Yang-Kui Gu; Tao Yu; Gui-Ping He; Yu-Long Xie; Zhi-Qiang Wang; Ting Liu; Si-Yuan Chen; Zhi-Xiang Zuo; Ming-Yuan Chen
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

2.  Use of a Smartphone Medical App Improves Complications and Quality of Life in Patients with Nasopharyngeal Carcinoma Who Underwent Radiotherapy and Chemotherapy.

Authors:  Ruiqing Di; Guowen Li
Journal:  Med Sci Monit       Date:  2018-09-04

3.  Neutral polysaccharide from Panax notoginseng enhanced cyclophosphamide antitumor efficacy in hepatoma H22-bearing mice.

Authors:  Yan-Hong Liu; Hua-Yan Qin; Yuan-Yuan Zhong; Shuang Li; Hua-Jing Wang; Hong Wang; Li-Ling Chen; Xiang Tang; Ya-Lin Li; Zhong-Yi Qian; Huai-Yu Li; Lei Zhang; Tong Chen
Journal:  BMC Cancer       Date:  2021-01-07       Impact factor: 4.430

4.  Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.

Authors:  Cheng Lin; Keyu Lin; Bin Zhang; Ying Su; Qiaojuan Guo; Tianzhu Lu; Yuanji Xu; Shaojun Lin; Jingfeng Zong; Jianji Pan
Journal:  Oncologist       Date:  2022-04-05       Impact factor: 5.837

Review 5.  MRI detection of suspected nasopharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Vineet Vijay Gorolay; Naomi Natasha Niles; Ya Ruth Huo; Navid Ahmadi; Kate Hanneman; Elizabeth Thompson; Michael Vinchill Chan
Journal:  Neuroradiology       Date:  2022-04-30       Impact factor: 2.995

6.  Compliance with National Guidelines on the Treatment of Stage II–IVB Nasopharyngeal Carcinoma in a Regional Cancer Center of Southern China

Authors:  Jia-Xiang Ye; Xia Liang; Jian Wei; Jing Zhou; Yu Liao; Yu-Lei Lu; Xia-Quan Tang; An-Yu Wang; Yong Tang
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.